275 related articles for article (PubMed ID: 25626314)
1. [Allogeneic hematopoietic stem cell transplantation for multiple myeloma].
Takase K; Miyamoto T
Nihon Rinsho; 2015 Jan; 73(1):107-13. PubMed ID: 25626314
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
Koehne G; Giralt S
Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
Servais S; Baron F; Beguin Y
Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
[TBL] [Abstract][Full Text] [Related]
4. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Nishihori T; Alsina M
Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: a concise review.
Salit RB; Bishop MR
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):247-52. PubMed ID: 21658650
[TBL] [Abstract][Full Text] [Related]
6. The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Bensinger WI
Leukemia; 2006 Oct; 20(10):1683-9. PubMed ID: 16888617
[TBL] [Abstract][Full Text] [Related]
7. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
8. Progress in allogeneic transplantation for multiple myeloma.
Gahrton G
Eur J Haematol; 2010 Oct; 85(4):279-89. PubMed ID: 20608964
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplantation in multiple myeloma.
Gahrton G
Recent Results Cancer Res; 2011; 183():273-84. PubMed ID: 21509689
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: role of allogeneic transplantation.
Pandit S; Vesole DH
Oncology (Williston Park); 2002 Sep; 16(9):1268-74; discussion 1274-6. PubMed ID: 12380950
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience.
Ramasamy K; Mahmood S; Lim Z; Corderoy S; Devereux S; Mufti GJ; Pagliuca A; Schey S
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):242-5. PubMed ID: 21575930
[TBL] [Abstract][Full Text] [Related]
14. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effect.
Zeiser R; Finke J
Eur J Cancer; 2006 Jul; 42(11):1601-11. PubMed ID: 16759847
[TBL] [Abstract][Full Text] [Related]
16. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma.
Nishihori T; Kharfan-Dabaja MA; Ochoa-Bayona JL; Bazarbachi A; Pasquini M; Alsina M
Hematol Oncol Stem Cell Ther; 2011; 4(1):1-9. PubMed ID: 21460601
[TBL] [Abstract][Full Text] [Related]
17. Role of stem cell transplantation.
Harousseau JL
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
[TBL] [Abstract][Full Text] [Related]
18. Role of allogeneic stem cell transplantation in multiple myeloma.
Thomson KJ; Peggs KS
Expert Rev Anticancer Ther; 2005 Jun; 5(3):455-64. PubMed ID: 16001953
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]